Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 8/20 | 0.37 |
| ▸ | CNR1 | P21554 | 7/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22488080 | 0.93 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2HSD17B10GLA | |
| SCHEMBL22930813 | 0.86 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HSD17B10CNR2 | |
| SCHEMBL21398242 | 0.86 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HSD17B10CNR2 | |
| SCHEMBL18481820 | 0.85 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL23583995 | 0.84 | NPC1 (0.38) | NPC1RAB9ASMN1; SMN2HSD17B10CNR2 | |
| SCHEMBL18516932 | 0.84 | CNR2 (0.45) | CNR2CNR1LTB4RLTB4R2 | |
| SCHEMBL22930725 | 0.84 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2HSD17B10GLA | |
| SCHEMBL19425824 | 0.83 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2HSD17B10GLA | |
| SCHEMBL22663604 | 0.82 | CNR2 (0.37) | RAB9ACNR2CNR1LTB4RLTB4R2 | |
| SCHEMBL23583873 | 0.81 | CNR2 (0.42) | CNR2CNR1LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361860-A1 | hTERT MODULATORS AND METHODS OF USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361860-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, TERF2, RB1 | NPC1 2570/4885RAB9A 3596/4885SMN1; SMN2 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.